Baudax Bio, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Capital Structure - Additional Information (Details)

Capital Structure - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands												12 Months Ended
	Feb. 08, 2021	Jan. 21, 2021	Dec. 18, 2020	Nov. 24, 2020	Oct. 19, 2020	May 29, 2020	Mar. 26, 2020	Feb. 13, 2020	Jan. 01, 2020	Nov. 21, 2019	Nov. 15, 2019	Dec. 31, 2020	Dec. 21, 2020	Dec. 31, 2019
Schedule Of Capitalization Equity [Line Items]
Common stock, shares authorized to issue												100,000,000		100,000,000
Common stock, par value												$ 0.01		$ 0.01
Proceeds from public offering, net of transaction costs												$ 23,085
Common stock in public offering							7,692,308
Proceeds from issuance of common stock underwriting discounts and commissions and offering expenses												$ 23,085
Placement agents cash fee percentage			6.00%	6.00%
Management fee percentage			1.00%	1.00%
Preferred stock, shares authorized												10,000,000
Preferred stock, par value												$ 0.01
Preferred stock, shares issued												0
Preferred stock, shares outstanding												0
Common stock, shares issued												48,688,480		9,350,709
Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Remaining contractual term												4 years 2 months 26 days
Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Remaining contractual term												3 months 25 days
March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock in public offering												8,836,663
Warrant to purchase of common stock												32,438
Proceeds from issuance of warrants												$ 2,538
Warrant to purchase of common stock												32,438
Exercise price of warrants												$ 0.01
March Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock in public offering												8,836,663
Warrant to purchase of common stock												32,438
Proceeds from issuance of warrants												$ 2,538
Warrant to purchase of common stock												32,438
Exercise price of warrants												$ 0.01
March Series A and Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock												549,231
Exercise price of warrants												$ 0.01
November Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock in public offering												7,276,583
Proceeds from issuance of warrants												$ 73
December Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock in public offering												6,050,430
Proceeds from issuance of warrants												$ 60
January Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		10,300,430
Offering price of warrant		$ 0.125
Exercise price of warrants		$ 1.60
Remaining contractual term		5 years
December Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock												10,300,430
Exercise price of warrants												$ 1.18	$ 1.18
February Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	11,000,000
Exercise price of warrants	$ 1.60
MAM Eagle Lender, LLC
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock						527,100
Common stock exercisable price per share						$ 4.59
March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock							7,692,308
Common stock exercisable price per share							$ 4.59
March Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock							7,692,308
Common stock exercisable price per share							$ 3.25
November Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock				10,126,583
Common stock exercisable price per share				$ 1.20
Common stock in direct offering				2,850,000
November Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs				$ 10,763
Common stock exercisable price per share				$ 0.01
Pre-funded warrants to purchase of common stock				7,276,583
November Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock				607,595
Common stock exercisable price per share				$ 1.48125
December Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock			10,300,430
Common stock exercisable price per share			$ 1.18
Common stock in direct offering			4,250,000
December Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Proceeds from public offering, net of transaction costs			$ 10,933
Common stock exercisable price per share			$ 0.01
Pre-funded warrants to purchase of common stock			6,050,430
December Placement Agent Warrants
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock			618,026
Common stock exercisable price per share			$ 1.45625
January Placement Agent Warrants \| January Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants		$ 2.00
Percentage of exercise price		125.00%
January Placement Agent Warrants \| January Warrants \| Subsequent Event \| Maximum
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock		618,026
Percentage of warrants issued to placement agent		6.00%
January Placement Agent Warrants \| December Series A Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Percentage of cash fee on gross proceeds		6.00%
Percentage of management fee on gross proceeds		1.00%
February Placement Agent Warrants \| February Warrants \| Subsequent Event
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants	$ 2.00
Percentage of cash fee on gross proceeds	6.00%
Percentage of management fee on gross proceeds	1.00%
February Placement Agent Warrants \| February Warrants \| Subsequent Event \| Maximum
Schedule Of Capitalization Equity [Line Items]
Warrant to purchase of common stock	660,000
Percentage of warrants issued to placement agent	6.00%
The Agreement
Schedule Of Capitalization Equity [Line Items]
Issuance of common stock upon separation												441,967
Common stock, par value								$ 0.01
Proceeds from public offering, net of transaction costs								$ 25,000
Proceeds from sales agreement												$ 3,612
Paid sales commission												3.00%
Warrant Exchange Agreements
Schedule Of Capitalization Equity [Line Items]
Common stock, shares issued					1,186,774
Warrant Exchange Agreements \| Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Warrants issued to purchase shares of common stock					0.2
Warrant Exchange Agreements \| Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Warrants issued to purchase shares of common stock					0.2
Warrant Exchange Agreements \| March Series A Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value					$ 0.01
Warrants expiration date					Apr. 26, 2021
Warrant Exchange Agreements \| March Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Common stock, par value					$ 0.01
Warrants expiration date					Apr. 26, 2021
Warrant Exchange Agreements \| March Series A and Series B Warrants
Schedule Of Capitalization Equity [Line Items]
Reclassification to equity upon warrant exchange					$ 21,858
Recro
Schedule Of Capitalization Equity [Line Items]
Right to receive common stock										1
Number of shares held for distribution of new shares											2.5
Issuance of common stock upon separation									45,874	9,396,583